Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation
Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation
复制标题
DOI：
10.1182/blood.v89.6.2184
复制
发表时间：
1997-03-15
期刊：
影响因子：
20.3
通讯作者：
Hiller, E
中科院分区：
文献类型：
--
作者：
Salat, C;Holler, E;Hiller, E
肝静脉闭塞病(VOD)是骨髓移植(BMT)后常见而严重的并发症，我们曾将纤溶酶原激活物抑制物-1(PAI-1)作为VOD的可能标记物，为了证实这一发现的意义，我们检测了186例因各种原因出现高胆红素血症>3 mg/dL的BMT患者中31例的PAI-1水平，其中23例经临床诊断并经活检证实，包括VOD(n=7)、肝脏急性移植物抗宿主病(GVHD)(n=7)和其他肝损伤(n=17)。PAI-1(Mean+/-SD)差异有统计学意义(P
Hepatic veno-occlusive disease (VOD) is a frequent and severe complication after bone marrow transplantation (BMT), We previously have described plasminogen activator inhibitor-1 (PAI-1) as a possible marker of VOD, To confirm the significance of this finding, we now determined PAI 1 levels in 31 of 186 consecutive patients undergoing BMT who developed hyperbilirubinemia greater than 3 mg/dL for various reasons, Diagnoses were made by clinical criteria and confirmed by biopsy in 23 of 31 patients, They included VOD (n = 7), acute graft-versus-host disease (GVHD) of the liver (n = 7), and other hepatic injury (n = 17). PAI-1 (mean +/- SD) was significantly (P